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Intensity-modulated radiation therapy for lymph node oligo-recurrence 




Background/Aim: Radical local therapy is generally not considered for patients with cancer metastasis 
or recurrence because the cancer has already spread throughout the body at the time of diagnosis and 
is thus difficult to cure. However, an increasing number of reports have suggested that the prognosis 
of these patients can be improved by local therapies such as surgery or radiotherapy if the number of 
affected regions is limited. This pathological condition was first defined as oligometastases by 
Hellman and Weichselbaum in 1995. They suggested that for many cancer types, a few metastases 
initially exist during the oligometastatic phase, after which the malignant cells acquire widespread 
metastatic potential. Theoretically, delivery of radical local therapy during the oligometastatic phase 
might improve the prognosis of patients who would otherwise be offered exclusively systemic therapy 
or palliative care. Oligo-recurrence, as a specific oligometastatic situation, was a concept proposed by 
Niibe in 2006. In oligorecurrence, the primary site should be controlled and all gross metastatic lesions 
can be treated by local therapy with radical intent (Niibe et al, 2010). In contrast, oligometastases is 
defined as a few metastases regardless of the status of the primary lesion. Patients with oligo-
recurrence are more likely to be cured compared with those with oligometastases.  
This study aimed to evaluate the effect of intensity-modulated radiation therapy (IMRT) on 
the clinical outcomes of patients with lymph node (LN) oligo-recurrence and a controlled primary 
tumor.  
Patients and Methods: We retrospectively reviewed the medical records of 21 patients diagnosed with 
LN oligo-recurrence who received IMRT with curative intent. Patients with tumor of various primary 
sites and histopathological types were included in this study.  
 
Results: The 3-year overall survival (OS) and in-field progression-free survival (PFS) rates were 75% 
and 52%, respectively (Figure 1). Statistical analysis showed that lower dose to the gross tumor 
volume (GTV) and larger GTV were significantly associated with poorer OS; adenocarcinoma and 
lower dose to GTV were significantly associated with poorer in-field PFS (Figure 2). No patients 
experienced severe adverse events.  
 
Conclusion: IMRT may provide a safe and effective treatment for patients with LN oligo-recurrence. 


































Figure 1. Kaplan-Meier plots of (a) OS, (b) in-field PFS, and (c) out-of-field PFS for all 21 patients. 


























Figure 2. Effects of potential prognostic factors on survival. (a) Effect of GTV (<20 cm3 vs. ≥20 cm3) 
on OS rate. (b) Effect of histopathologic type (adenocarcinoma vs. non-adenocarcinoma) on in-field 
PFS rate. (c) Effect of histopathologic type (squamous cell carcinoma vs. non-squamous cell 
carcinoma) on out-of-field PFS rate. (d) Effect of age (<70 vs ≥70 years) on out-of-field PFS rate. OS, 






















Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8--10. 
 
Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: The new era of cancer therapy. Jpn J 



















 Publication list 
 
Ⅰ Intensity-modulated radiation therapy for lymph node oligo-recurrence 
Sato, A., Omura, M., Minagawa, Y., Matsui, K., Shirata, R., Hongo, H., Hashimoto, H.,  
Toshihiro, M., Inoue, T. and Hata, M.:In vivo, Vol: 34, 2587-2593, 2020 
 
 
 
 
 
